These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 11684568)
21. What is the impact of PRIME on real-life diabetic nephropathy? Ruilope LM Int J Clin Pract; 2004 Mar; 58(3):268-76. PubMed ID: 15117095 [TBL] [Abstract][Full Text] [Related]
22. [Current treatment of diabetic nephropathy in patients with type II diabetes mellitus. Most recent progress]. de Alvaro F Nefrologia; 2001; 21 Suppl 3():76-82. PubMed ID: 11642211 [No Abstract] [Full Text] [Related]
23. Losartan for hypertension. Med Lett Drugs Ther; 1995 Jun; 37(951):57-8. PubMed ID: 7783693 [No Abstract] [Full Text] [Related]
24. [Evidence for the benefits of ACE inhibitors and AII antagonists in slowing progressive renal failure in diabetes]. Suzuki H Nihon Rinsho; 2002 Oct; 60 Suppl 10():323-8. PubMed ID: 12430248 [No Abstract] [Full Text] [Related]
25. Renoprotection in Type 2 diabetes: blockade of the renin-angiotensin system with angiotensin II receptor blockers. Swift PA; MacGregor GA J Renin Angiotensin Aldosterone Syst; 2001 Sep; 2(3):170-3. PubMed ID: 11881118 [No Abstract] [Full Text] [Related]
26. [Large scale clinical trials in prevention of end-stage renal disease due to type 2 diabetes with angiotensin receptor antagonists]. Suzuki H Nihon Rinsho; 2002 Oct; 60(10):2040-4. PubMed ID: 12397704 [TBL] [Abstract][Full Text] [Related]
27. Irbesartan prevents the progression of kidney disease or death in patients with type 2 diabetes and high blood pressure. Cardiovasc J S Afr; 2001; 12(4):240-1. PubMed ID: 11766617 [No Abstract] [Full Text] [Related]
28. Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats. Kalender B; Oztürk M; Tunçdemir M; Uysal O; Dagistanli FK; Yegenaga I; Erek E Acta Histochem; 2002; 104(2):123-30. PubMed ID: 12086332 [TBL] [Abstract][Full Text] [Related]
29. [What is a good marker for better antihypertensive therapy in diabetic patients when coexisting with hypertension]. Eguchi K; Kario K; Shimada K Nihon Rinsho; 2002 Sep; 60 Suppl 9():679-84. PubMed ID: 12387069 [No Abstract] [Full Text] [Related]
30. [Dosage equivalents of AT1-receptor antagonists available in Germany]. Dominiak P; Häuser W Dtsch Med Wochenschr; 2003 Oct; 128(44):2315-8. PubMed ID: 14593575 [No Abstract] [Full Text] [Related]
31. AT1-receptor antagonists for the treatment of chronic heart failure. Baan J Cardiovasc Res; 1999 Jan; 41(1):14-5. PubMed ID: 10325947 [No Abstract] [Full Text] [Related]
32. [Angiotensin receptor antagonist for therapy of patients with hypertension]. Rakugi H; Ogihara T Nihon Rinsho; 1997 Aug; 55(8):2075-80. PubMed ID: 9284426 [TBL] [Abstract][Full Text] [Related]
37. [Angiotensin II type-1 receptor antagonists and diabetes mellitus]. Schnack C; Schernthaner G Wien Med Wochenschr; 2001; 151(7-8):165-8. PubMed ID: 11450165 [TBL] [Abstract][Full Text] [Related]
38. A new class of antihypertensive therapy: angiotensin II receptor antagonists. Ellis ML; Patterson JH Pharmacotherapy; 1996; 16(5):849-60. PubMed ID: 8888079 [TBL] [Abstract][Full Text] [Related]
39. Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes. Jerums G; Cooper ME; Gilbert RE; Atkins RC Med J Aust; 2001 Oct; 175(8):397-9. PubMed ID: 11700829 [No Abstract] [Full Text] [Related]
40. [Type 2 diabetes and nephropathy--new studies, new treatment strategies?]. Os I; Stenehjem A; Høieggen A; Draganov B; Jenssen T; Holdaas H Tidsskr Nor Laegeforen; 2002 Apr; 122(9):918-20. PubMed ID: 12082835 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]